This Pharma Stock Shuts Overseas Unit; Here’s Why

Mankind Pharma opened at Rs 2,040.10 and moved higher to touch an Intraday high of Rs 2,095.70, while the low stood at Rs 2,014.70. It eventually closed at Rs 2,077.40, registering a marginal decline of 0.08 per cent, indicating a muted market reaction to the announcement made by the company, that its Board of Directors has approved the closure of its wholly owned subsidiary, Mankind Pharma Lanka (Private) Limited, incorporated in Sri Lanka.

Subsidiary Closure Approved
The decision was taken during the board meeting held today, in line with Regulation 30 of SEBI (LODR) Regulations. The company stated that due to changes in regulatory requirements, the originally planned business objectives for the subsidiary are no longer viable.

The company also clarified that the Sri Lanka-based subsidiary had no active business operations and was not considered a material subsidiary. As a result, the closure is not expected to have any significant impact on the company’s overall operations.

No Material Business Impact
Mankind Pharma emphasized that since the subsidiary was non-operational, the winding-up process will not affect its core business activities. The move appears to be a strategic step to streamline operations and focus on more viable markets.

About the Company
Mankind Pharma Limited, incorporated in 1995, is engaged in the development, manufacturing, and marketing of pharmaceutical formulations across acute and chronic therapeutic segments. The company also has a strong presence in the consumer healthcare space with a diverse portfolio of products.

Share your views in the comments below.

Disclaimer: This article is for informational purposes only and not investment advice.